Advanced GIST mainly contains imatinib‐insensitive mutants or secondary mutations in oncogenic KIT or PDGFRα,7, 15 which confer resistance not only to imatinib but also to other KIT TKIs approved for advanced GIST. Here, KIT is linked to gastrointestinal stromal tumor.